Supernus Pharmaceuticals (SUPN) Goodwill & Intangibles (2016 - 2026)
Supernus Pharmaceuticals has reported Goodwill & Intangibles over the past 15 years, most recently at $694.3 million for Q4 2025.
- Quarterly Goodwill & Intangibles rose 8.67% to $694.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $694.3 million through Dec 2025, up 8.67% year-over-year, with the annual reading at $694.3 million for FY2025, 8.67% up from the prior year.
- Goodwill & Intangibles was $694.3 million for Q4 2025 at Supernus Pharmaceuticals, down from $742.6 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $902.2 million in Q4 2021 and troughed at $424.6 million in Q3 2021.
- The 5-year median for Goodwill & Intangibles is $706.8 million (2023), against an average of $698.5 million.
- The largest YoY upside for Goodwill & Intangibles was 1751.85% in 2021 against a maximum downside of 13.6% in 2021.
- A 5-year view of Goodwill & Intangibles shows it stood at $902.2 million in 2021, then dropped by 9.17% to $819.5 million in 2022, then fell by 12.52% to $716.9 million in 2023, then decreased by 10.88% to $638.9 million in 2024, then grew by 8.67% to $694.3 million in 2025.
- Per Business Quant, the three most recent readings for SUPN's Goodwill & Intangibles are $694.3 million (Q4 2025), $742.6 million (Q3 2025), and $598.3 million (Q2 2025).